Mason, H. Et Al. 2017. Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors. Annual Meeting of the American-Association-for-Cancer-Research (AACR) , (Washington, Kiribati).

Mason, H., Scrace, S., Testar, R., Rainard, J., Talab, F., Poonawala, R., ... Smith, P.(2017). Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors . Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, Kiribati

Mason, ABİS Et Al. "Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors," Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, Kiribati, 2017

Mason, ABİS Et Al. "Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors." Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Washington, Kiribati, 2017

Mason, H. Et Al. (2017) . "Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors." Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Washington, Kiribati.

@conferencepaper{conferencepaper, author={ABİS DESTEK Et Al. }, title={Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors}, congress name={Annual Meeting of the American-Association-for-Cancer-Research (AACR)}, city={Washington}, country={Kiribati}, year={2017}}